Michele Iuliani

10PUBLICATIONS
22CO-AUTHORS
Gene and molecular therapyPredictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Solid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 28, 2024
S-p-bromobenzyl-glutathione cyclopentyl diester (BBGC) as novel therapeutic strategy to enhance trabectedin anti-tumor effect in soft tissue sarcoma preclinical models.

F Pantano, S Simonetti, M Iuliani

|Jun 22, 2024
Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC).

Michele Iuliani, Sonia Simonetti, Leonardo Cristofani

|Sep 23, 2022
Osteoblast Secretome Modulated by Abiraterone Treatment Affects Castration Resistant Prostate Cancer Cell Proliferation.

Michele Iuliani, Sonia Simonetti, Giulia Ribelli

|Sep 14, 2022
Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma.

Sonia Simonetti, Michele Iuliani, Marco Stellato

|May 28, 2022
Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer Patients.

Francesco Pantano, Francesca Zalfa, Michele Iuliani

|Mar 10, 2022
Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment.

Michele Iuliani, Sonia Simonetti, Giulia Ribelli

Pageof 2

Frequent Collaborators

3 joint publications

Sonia Simonetti

2 joint publications

Andrea Napolitano

1 joint publications

M J Guillen

1 joint publications

L Nibid